Fresenius Medical Care, the world’s largest provider of dialysis products and services, has filed the annual report 2019 on form 20-F with the U.S. Securities and Exchange Commission (SEC).
Solid Q4 performance; Full year guidance achieved; Investments in home dialysis and growth markets as planned; Cost optimization initiatives as planned; 23rd dividend increase proposed; Outlook 2020 confirmed
Fresenius Medical Care, the world’s largest provider of dialysis products and services, today successfully placed bonds in three tranches with an aggregate volume of €1.75 billion.
Continued strong organic revenue growth across all regions; Record growth in home dialysis in North America; Improved earnings growth despite negative ESCO effect; Cost optimization initiatives on track; Outlook 2019 confirmed
Spectra Laboratories broke ground on a 200,000-square-foot laboratory in Southaven, Mississippi yesterday. The project is expected to create more than 300 jobs over the next three years.
Underlying business development in line with expectations; Continued strong organic revenue growth; Healthy growth in the U.S. dialysis business
